



IAP6 Rec'd PCT/PTO 25 JUL 2006

CASE ON/4-32548A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV722488160KS

Express Mail Label Number

July 25, 2006

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL APPLICATION OF

JOSEPH ALEXANDER LASKY

INTERNATIONAL APPLICATION NO: PCT/IB03/02794

FILED: 17 JUNE 2003

U.S. APPLICATION NO.: 10/518,988

35 USC §371 DATE:

FOR: 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO]PHENYL]-BENZAMIDE FOR TREATING PULMONARY FIBROSIS

MS: Missing Parts

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

PETITION TO REVIVE UNDER 37 CFR 1.137(b) AND
RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS

Sir:

Applicants respectfully request that the above-identified application be revived under the provisions of 37 CFR 1.137(b).

This application became abandoned for Applicant's failure to timely file a response to the Notification of Missing Requirements. However, Applicants never received the Notification of Missing Requirements Under 35 U.S.C. 371 In The United States Designated/Elected Office (DO/EO/US).

In response to the Notice of Abandonment, Applicants submit a fully executed Declaration and Power of Attorney Please charge the \$130 surcharge fee under 37 CFR §1.16(e) to Deposit Account No. 19-0134 in the name of Novartis.


The Notification of Missing Requirements Under 35 U.S.C. 371 requests that the nucleotide and/or amino sequence disclosure comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825. However, the present application does not contain a nucleotide or amino acid sequence. Therefore it is respectfully requested that this requirement be withdrawn from the Notification of Missing Requirements Under 35 U.S.C. 371.

In accordance with 37 CFR 1.137(b)(2), the Commissioner is hereby authorized to charge the fee of \$1,500 required by 37 CFR 1.17(m) to Deposit Account No. 19-0134 in the name of Novartis. A duplicate copy of this Petition is also enclosed.

The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7852
Date: 2/25/06


Oona A. Jackson
Attorney for Applicant
Reg. No. 48,152



OAT

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/518,988	Joseph Alexander Lasky	ON/4-32548A

INTERNATIONAL APPLICATION NO.

PCT/IB03/02794

I.A. FILING DATE

PRIORITY DATE

06/17/2003

06/28/2002

001095
 NOVARTIS
 CORPORATE INTELLECTUAL PROPERTY
 ONE HEALTH PLAZA 104/3
 EAST HANOVER, NJ 07936-1080

CONFIRMATION NO. 1365

**371
 ABANDONMENT/TERMINATION
 LETTER**




OC000000019566000

Date Mailed: 07/12/2006

NOTIFICATION OF ABANDONMENT

The United States Patent and Trademark Office in its capacity as a Designated / Elected Office (37 CFR 1.495) has made the following determination:

- failed to respond to notice of missing part mailed 11/21/05



Therefore, the above identified application failed to meet the requirements of 35 U.S.C. 371 and 37 CFR 1.495, and is ABANDONED AS TO THE UNITED STATES OF AMERICA.

VONDA M WALLACE

Telephone: (703) 308-9140 EXT 225

PART 1 - ATTORNEY/APPLICANT COPY

FORM PCT/DO/EO/909 (371 Abandonment Notice)